Profile of gantenerumab and its potential in the treatment of Alzheimer’s disease

References

• Thies W Bleiler L Alzheimer’s Association 2013 Alzheimer’s disease facts and figures Alzheimers Dement 2013 9 2 208 245 23507120
   PubMed Web of Science ®Google Scholar
• Selkoe DJ Alzheimer’s disease is a synaptic failure Science 2002 298 5594 789 791 12399581
   PubMed Web of Science ®Google Scholar
• Francis PT Nordberg A Arnold SE A preclinical view of cholinesterase inhibitors in neuroprotection: do they provide more than symptomatic benefits in Alzheimer’s disease? Trends Pharmacol Sci 2005 26 2 104 111 15681028
   PubMed Web of Science ®Google Scholar
• Zhou J Fu Y Tang XC Huperzine A and donepezil protect rat pheochromocytoma cells against oxygen-glucose deprivation Neurosci Lett 2001 306 1–2 53 56 11403956
   PubMed Web of Science ®Google Scholar
• Wang ZF Zhou J Tang XC Huperzine B protects rat pheochromocytoma cells against oxygen-glucose deprivation-induced injury Acta Pharmacol Sin 2002 23 12 1193 1198 12466060
   PubMed Web of Science ®Google Scholar
• Tabet N Acetylcholinesterase inhibitors for Alzheimer’s disease: anti-inflammatories in acetylcholine clothing! Age Ageing 2006 35 4 336 338 16788077
   PubMed Web of Science ®Google Scholar
• Shytle RD Mori T Townsend K Cholinergic modulation of microglial activation by alpha 7 nicotinic receptors J Neurochem 2004 89 2 337 343 15056277
   PubMed Web of Science ®Google Scholar
• Pollak Y Gilboa A Ben-Menachem O Ben-Hur T Soreq H Yirmiya R Acetylcholinesterase inhibitors reduce brain and blood interleukin-1beta production Ann Neurol 2005 57 5 741 745 15852394
   PubMed Web of Science ®Google Scholar
• Xiao XQ Wang R Tang XC Huperzine A and tacrine attenuate beta-amyloid peptide-induced oxidative injury J Neurosci Res 2000 61 5 564 569 10956426
   PubMed Web of Science ®Google Scholar
• Klugman A Naughton DP Isaac M Shah I Petroczi A Tabet N Antioxidant enzymatic activities in Alzheimer’s disease: the relationship to acetylcholinesterase inhibitors J Alzheimers Dis 2012 30 3 467 474 22451323
   PubMed Web of Science ®Google Scholar
• Hardy J Selkoe DJ The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics Science 2002 297 5580 353 356 12130773
   PubMed Web of Science ®Google Scholar
• Findeis MA Peptide inhibitors of beta amyloid aggregation Curr Top Med Chem 2002 2 4 417 423 11966464
   PubMedGoogle Scholar
• Nakagami Y Nishimura S Murasugi T A novel compound RS-0466 reverses beta-amyloid-induced cytotoxicity through the Akt signaling pathway in vitro Eur J Pharmacol 2002 457 1 11 17 12460638
   PubMed Web of Science ®Google Scholar
• Nakagami Y Nishimura S Murasugi T A novel beta-sheet breaker, RS-0406, reverses amyloid beta-induced cytotoxicity and impairment of long-term potentiation in vitro Br J Pharmacol 2002 137 5 676 682 12381681
   PubMed Web of Science ®Google Scholar
• Walsh DM Klyubin I Shankar GM The role of cell-derived oligomers of Abeta in Alzheimer’s disease and avenues for therapeutic intervention Biochem Soc Trans 2005 33 Pt 5 1087 1090 16246051
   PubMed Web of Science ®Google Scholar
• Toyn JH Rowley A Matsuoka Y Tomita T Imbimbo BP γ-Secretase Pharmacology: What Pharmacology Will Work for Alzheimer’s Disease? Int J Alzheimers Dis 2013 2013 849128 23710414
   PubMedGoogle Scholar
• Leissring MA Proteolytic degradation of the amyloid beta-protein: the forgotten side of Alzheimer’s disease Curr Alzheimer Res 2006 3 5 431 435 17168642
   PubMedGoogle Scholar
• Selkoe DJ Clearing the brain’s amyloid cobwebs Neuron 2001 32 2 177 180 11683988
   PubMed Web of Science ®Google Scholar
• Schenk D Amyloid-beta immunotherapy for Alzheimer’s disease: the end of the beginning Nat Rev Neurosci 2002 3 10 824 828 12360327
   PubMed Web of Science ®Google Scholar
• Senior K Dosing in phase II trial of Alzheimer’s vaccine suspended Lancet Neurol 2002 1 1 3 12849527
   PubMed Web of Science ®Google Scholar
• Kerchner GA Boxer AL Bapineuzumab Expert Opin Biol Ther 2010 10 7 1121 1130 20497044
   PubMed Web of Science ®Google Scholar
• Samadi H Sultzer D Solanezumab for Alzheimer’s disease Expert Opin Biol Ther 2011 11 6 787 798 21504387
   PubMed Web of Science ®Google Scholar
• Vellas B Carrillo MC Sampaio C EU/US/CTAD Task Force Members Designing drug trials for Alzheimer’s disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force Alzheimers Dement 2013 9 4 438 444 23809364
   PubMed Web of Science ®Google Scholar
• Eli Lilly and Company Lilly provides update on next stepsfor Solanezumab 12 12 2012 Available from: http://newsroom.lilly.com/releasedetail.cfm?ReleaseID=726309 Accessed October 20, 2013
   Google Scholar
• Bohrmann B Baumann K Benz J Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β J Alzheimers Dis 2012 28 1 49 69 21955818
   PubMed Web of Science ®Google Scholar
• Koenigsknecht-Talboo J Meyer-Luehmann M Parsadanian M Rapid microglial response around amyloid pathology after systemic anti-Abeta antibody administration in PDAPP mice J Neurosci 2008 28 52 14156 14164 19109498
   PubMed Web of Science ®Google Scholar
• Dolman NP Troop HM More JC Synthesis and pharmacology of willardiine derivatives acting as antagonists of kainate receptors J Med Chem 2005 48 24 7867 7881 16302825
   PubMed Web of Science ®Google Scholar
• Dargan SL Clarke VR Alushin GM ACET is a highly potent and specific kainate receptor antagonist: characterisation and effects on hippocampal mossy fibre function Neuropharmacology 2009 56 1 121 130 18789344
   PubMed Web of Science ®Google Scholar
• Nisticò R Pignatelli M Piccinin S Mercuri NB Collingridge G Targeting synaptic dysfunction in Alzheimer’s disease therapy Mol Neurobiol 2012 46 3 572 587 22914888
   PubMed Web of Science ®Google Scholar
• Errico F Nisticò R Palma G Increased levels of d-aspartate in the hippocampus enhance LTP but do not facilitate cognitive flexibility Mol Cell Neurosci 2008 37 2 236 246 17981050
   PubMed Web of Science ®Google Scholar
• Errico F Nisticò R Napolitano F Increased D-aspartate brain content rescues hippocampal age-related synaptic plasticity deterioration of mice Neurobiol Aging 2011 32 12 2229 2243 20097447
   PubMed Web of Science ®Google Scholar
• Errico F Nisticò R Napolitano F Persistent increase of D-aspartate in D-aspartate oxidase mutant mice induces a precocious hippocampal age-dependent synaptic plasticity and spatial memory decay Neurobiol Aging 2011 32 11 2061 2074 20031274
   PubMed Web of Science ®Google Scholar
• Molinaro P Viggiano D Nisticò R Na+ -Ca2+ exchanger (NCX3) knock-out mice display an impairment in hippocampal long-term potentiation and spatial learning and memory J Neurosci 2011 31 20 7312 7321 21593315
   PubMed Web of Science ®Google Scholar
• Bonito-Oliva A Pignatelli M Spigolon G Cognitive Impairment and Dentate Gyrus Synaptic Dysfunction in Experimental Parkinsonism Biol Psychiatry Epub 3 28 2013
   Web of Science ®Google Scholar
• Pignatelli M Vollmayr B Richter SH Enhanced mGlu5-receptor dependent long-term depression at the Schaffer collateral-CA1 synapse of congenitally learned helpless rats Neuropharmacology 2013 66 339 347 22709946
   PubMed Web of Science ®Google Scholar
• Pignatelli M Feligioni M Piccinin S Molinaro G Nicoletti F Nisticò R Synaptic plasticity as a therapeutic target in the treatment of autism-related single-gene disorders Curr Pharm Des Epub 2 13 2013
   Web of Science ®Google Scholar
• Nisticò R Mango D Mandolesi G Inflammation subverts hippocampal synaptic plasticity in experimental multiple sclerosis PLoS One 2013 8 1 e54666 23355887
   PubMed Web of Science ®Google Scholar
• Balducci C Mehdawy B Mare L The γ-secretase modulator CHF5074 restores memory and hippocampal synaptic plasticity in plaque-free Tg2576 mice J Alzheimers Dis 2011 24 4 799 816 21321397
   PubMed Web of Science ®Google Scholar
• La Rosa LR Matrone C Ferraina C Age-related changes of hippocampal synaptic plasticity in AβPP-null mice are restored by NGF through p75 NTR J Alzheimers Dis 2013 33 1 265 272 22954667
   PubMed Web of Science ®Google Scholar
• Knobloch M Farinelli M Konietzko U Nitsch RM Mansuy IM Abeta oligomer-mediated long-term potentiation impairment involves protein phosphatase 1-dependent mechanisms J Neurosci 2007 27 29 7648 7653 17634359
   PubMed Web of Science ®Google Scholar
• Zago W Buttini M Comery TA Neutralization of soluble, synaptotoxic amyloid β species by antibodies is epitope specific J Neurosci 2012 32 8 2696 2702 22357853
   PubMed Web of Science ®Google Scholar
• Dodart JC Bales KR Gannon KS Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer’s disease model Nat Neurosci 2002 5 5 452 457 11941374
   PubMed Web of Science ®Google Scholar
• Ostrowitzki S Deptula D Thurfjell L Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab Arch Neurol 2012 69 2 198 207 21987394
   PubMedGoogle Scholar
• Boche D Nicoll JA The role of the immune system in clearance of Abeta from the brain Brain Pathol 2008 18 2 267 278 18363937
   PubMed Web of Science ®Google Scholar
• Nicoll JA Barton E Boche D Abeta species removal after abeta42 immunization J Neuropathol Exp Neurol 2006 65 11 1040 1048 17086100
   PubMed Web of Science ®Google Scholar
• Giuffrida ML Caraci F Pignataro B Beta-amyloid monomers are neuroprotective J Neurosci 2009 29 34 10582 10587 19710311
   PubMed Web of Science ®Google Scholar